A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

Pain Medicine

Volumn 6, Issue 5, 2005, Pages 346-356

  Raskin, Joel ^a   Pritchett, Yili L ^a   Wang, Fujun ^a   D'Souza, Deborah N ^a   Waninger, Amy L ^a   Iyengar, Smriti ^a   Wernicke, Joachim F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Diabetic Neuropathy; Duloxetine; Norepinephrine; Pain; Serotonin

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MELENA; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UROLITHIASIS; VOMITING;

AGED; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 28444459170     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2005.00061.x     Document Type: Article

References (33)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabetes Med 1997;14(suppl 5):S1-85.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
3. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-7.
4. Boulton AJM, Rayaz AM, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27(6):1458-86.
5. Eastman RC. Neuropathy in diabetes. In: National Diabetes Data Group, editors. Diabetes in America, 2nd Edition. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468. 1995:339-48.
6. Callisi PT, Jaber LA. Peripheral diabetic neuropathy: Current concepts in treatment. Ann Pharmacother 1995;29:769-77.
7. Courteix C, Eschalier A, Laverenne J. Streptozocin-induced diabetic rats: Behavioral evidence for a model of chronic pain. Pain 1993;53:81-8.
8. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63.
9. Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-38.
10. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: Anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616(1-2):200-10.
11. Coderre TJ, Katz J. Peripheral and central hyperexcitability: Differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20(3):404-19.
12. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43:205-18.
13. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RMA. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-84.
14. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants-Potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222.
15. Detke M, Goldstein D, Lu Y, Iyengar S, Lee T. Efficacy of duloxetine in the treatment of the pain associated with diabetic neuropathy. Diabetologia 2003;46(suppl2):A315.
16. Wernicke J, Lu Y, D'Souza D, Waninger A, Tran P. Antidepressants: Duloxetine at doses of 60 mg QD and 60 mg BID is effective in the treatment of diabetic neuropathic pain (DNP). J Pain 2004;5(suppl 1):S48.
17. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-FV and ICD-10. J Clin Psychiatry 1998;59:1-12.
19. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
20. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
21. Hamilton M. A rating scale for depression 1960. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6(4):278-96.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised. U.S. Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health; 1976;76-338.
24. Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF. Drug Inf J 2001;35:1215-25.
25. Retherford RD, Choe MK. Statistical methods for causal analysis. New York: John Wiley & Sons, Inc.; 1993.
26. Lu Y. An application of path analysis in the design of clinical trails. Proceedings of the Biopharmaceutical Section, ASA, 2003;2576-82.
27. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58.
28. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400.
29. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63(4):308-15.
30. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36(6):383-90.
31. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36(4):106-32.
32. Goldstein DJ, Mallinckrodt CH, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 2002;63(3):225-31.
33. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45(l):17-28.